Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2013 - 2026)

Amphastar Pharmaceuticals' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 9.62% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $32.3 million (down 5.24% YoY), while the FY2025 annual figure was $31.6 million, up 11.86% from the prior year.
• Depreciation & Amortization (CF) was $8.1 million for Q1 2026 at Amphastar Pharmaceuticals, up from $8.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $9.8 million in Q3 2024 to a low of $2.7 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $6.7 million across 5 years, with a median of $7.9 million in 2025.
• Biggest YoY gain for Depreciation & Amortization (CF) was 215.9% in 2024; the steepest drop was 24.84% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.4 million in 2022, then soared by 180.86% to $9.7 million in 2023, then declined by 24.84% to $7.3 million in 2024, then grew by 10.57% to $8.0 million in 2025, then climbed by 0.67% to $8.1 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $8.1 million (Q1 2026), $8.0 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.